Arovent-ODT
Generic Name
Montelukast
Manufacturer
Incepta Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| arovent odt 4 mg tablet | ৳ 6.00 | ৳ 60.00 |
Description
Overview of the medicine
Arovent-ODT 4 mg Tablet contains Montelukast, a leukotriene receptor antagonist. It is primarily used for the management and prevention of asthma and for the relief of symptoms of seasonal and perennial allergic rhinitis. The ODT formulation is designed for easy administration, especially in children or individuals who have difficulty swallowing tablets.
Uses & Indications
Dosage
Adults
The 4 mg ODT formulation is typically for pediatric patients. Adults with asthma or allergic rhinitis usually take a 10 mg tablet once daily in the evening.
Elderly
No dosage adjustment is generally required for elderly patients based on age, but caution should be exercised and a physician consulted.
Renal_impairment
No dosage adjustment is required in patients with renal impairment.
Pediatric_2_to_5_years
For pediatric patients 2 to 5 years of age: one 4 mg ODT once daily in the evening.
Pediatric_6_to_14_years
For pediatric patients 6 to 14 years of age: one 5 mg ODT once daily in the evening (Note: Arovent-ODT also available in 5mg strength).
Pediatric_below_2_years
Safety and effectiveness in pediatric patients younger than 2 years of age with asthma or perennial allergic rhinitis have not been established.
How to Take
Arovent-ODT 4 mg Tablet should be taken orally once daily in the evening. The orally disintegrating tablet should not be swallowed whole. It may be placed directly on the tongue to dissolve and then swallowed with saliva, or it may be chewed. It can be taken with or without food.
Mechanism of Action
Montelukast selectively antagonizes the cysteinyl leukotriene 1 (CysLT1) receptor. Cysteinyl leukotrienes (LTC4, LTD4, LTE4) are potent inflammatory eicosanoids released from various cells, including mast cells and eosinophils, involved in asthmatic and allergic reactions. By blocking the CysLT1 receptor, montelukast inhibits the bronchoconstriction and inflammatory effects mediated by these leukotrienes.
Pharmacokinetics
Onset
Clinical improvement for asthma is generally observed within 1 day.
Excretion
Montelukast and its metabolites are primarily excreted in the feces via the bile (approximately 86%); less than 0.2% is excreted in urine.
Half life
The mean plasma elimination half-life is 2.7 to 5.5 hours.
Absorption
Rapidly absorbed after oral administration. Mean oral bioavailability is 64-73%. Peak plasma concentrations (Tmax) are reached approximately 2-4 hours after administration.
Metabolism
Extensively metabolized in the liver, primarily by cytochrome P450 enzymes CYP3A4, CYP2C9, and CYP2C8.
Side Effects
Contraindications
- •Hypersensitivity to Montelukast or any component of the formulation.
- •Not indicated for the reversal of bronchospasm in acute asthma attacks; patients should be advised to have appropriate rescue medication available.
Drug Interactions
Rifampin
Co-administration with rifampin may decrease montelukast plasma concentrations, although dose adjustment is generally not recommended.
Phenobarbital
Co-administration with phenobarbital may decrease the area under the plasma concentration-time curve (AUC) of montelukast by approximately 40%, requiring clinical monitoring for reduced efficacy.
Other Medications
Montelukast has been safely co-administered with many commonly prescribed drugs in asthma and allergic rhinitis without significant interactions, including thyroid hormones, sedatives, non-steroidal anti-inflammatory agents, benzodiazepines, and oral corticosteroids.
Storage
Store in a cool, dry place, below 30°C. Protect from light and moisture. Keep out of reach of children.
Overdose
In post-marketing experience and clinical studies, there have been reports of acute overdose with montelukast. Symptoms included abdominal pain, somnolence, thirst, headache, vomiting, and psychomotor hyperactivity. Management is supportive and symptomatic; no specific antidote is known.
Pregnancy & Lactation
Pregnancy Category B. Studies in animals have not shown harm to the fetus. There are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if clearly needed. Montelukast is excreted in breast milk; caution should be exercised when administered to a nursing woman.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
24 months from the date of manufacture.
Availability
Pharmacies, Hospitals
Approval Status
Approved
Patent Status
Generic available
WHO Essential Medicine
YesAlternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in